Moderna Inc (NASDAQ:MRNA, XETRA:0QF) reported fourth quarter 2025 results that exceeded Wall Street expectations, sending its shares up about 11% on Friday. The company posted a net loss of $2.11 per
Moderna Inc. (NASDAQ: MRNA) on Friday reported a fourth-quarter loss of $2.11, beating the expected loss of $2.59, lower than a loss of $2.91 a year ago.
Moderna (MRNA) came out with a quarterly loss of $2.11 per share versus the Zacks Consensus Estimate of a loss of $2.6. This compares to a loss of $2.5 per share a year ago.
Moderna stock popped Friday after the company reported better-than-expected fourth-quarter sales and reiterated its 2026 outlook.
Moderna (NASDAQ: MRNA) reported fourth-quarter results Friday morning that beat Wall Street's muted expectations, delivering revenue of $678 million against estimates of $663 million and a loss of $2.
Moderna said it continues to target 10% revenue growth this year, as the company's fourth-quarter loss narrowed from a year earlier.
Stock News Tech slump hits indexes: A broad risk-off move saw Apple (AAPL) and Cisco (CSCO) lead declines, while Applied Materials (AMAT) rallied on upbeat AI t
Moderna posts a fourth-quarter loss of $2.11 a share on revenue of $678 million.

Moderna beats fourth-quarter revenue estimates

07:06am, Friday, 13'th Feb 2026
Moderna reported fourth-quarter revenue above Wall Street estimates on Friday, banking on better-than-expected sales of its COVID-19 vaccine in the U.S.
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) reported fourth quarter 2025 results that exceeded Wall Street expectations, sending its shares up about 11% on Friday....
Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11) Reports full-year revenue of $1.9 billion, GAAP net loss of $(2.8) billion and GAAP diluted EPS
Pharma stock Moderna (MRNA) is experiencing a sharp pullback from its Jan. 22, 52-week high of $55.20. Last seen down 3.5% at $39.08, the shares are headed for their third-straight weekly loss.

Moderna: Stock to Avoid or Bad News Buy?

11:10am, Thursday, 12'th Feb 2026
Moderna is working to build a seasonal vaccines portfolio to spur growth. The FDA this week said it won't review the biotech's flu vaccine candidate.
Stock News Futures edge up as jobs data and earnings mix: U.S. stock futures inched higher after January payrolls rose 130,000 with unemployment at 4.3%, compli
Moderna Inc (NASDAQ:MRNA) has delivered a 37% gain year-to-date, dramatically outpacing the biotech sector's 0.4% YTD return.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE